Table 1 Characteristics of study patients

Patients, n (%)

235 (100)

50 (21.3)

185 (78.7)

Age, mean (±SD)

66.1 (±8.5)

67.6 (±8.8)

65.7 (±8.4)

.266^a

Gender, n (%)

.356^b

 Female

62 (26.4)

14 (28.0)

48 (25.9)

 Male

173 (73.6)

36 (72.0)

137 (74.1)

Histology, n (%)

< .001^b

 SCC

124 (52.8)

17 (34.0)

107 (57.8)

 AC

76 (32.3)

21 (42.0)

55 (29.8)

 NOS/ others

35 (14.9)

12 (24.0)

23 (12.4)

Treatment, n (%)

< .001^b

 Chemoradiotherapy

211 (89.8)

26 (52.0)

185 (100)

 Surgery

24 (10.2)

24 (48.0)

UICC stage (8^thedition), n (%)

< .001^b

 IIIa

67 (28.5)

23 (46.0)

44 (23.8)

 IIIb

113 (48.1)

22 (44.0)

91 (49.2)

 IIIc

55 (23.4)

5 (10.0)

50 (27.0)

PET parameter, median (IQR)

 MTV

73.3 (29 - 129)

64.9 (21 - 96)

76.4 (33 - 135)

< .001^c

 TLG

385.1 (136 - 716)

276.3 (107 - 601)

414.9 (162 - 832)

< .001^c

 SULpeak

10.0 (7 - 13)

9.0 (7 - 11)

10.2 (8 - 13)

< .001^c

 SUVmax

15.8 (12 - 20)

14.6 (12 - 17)

16.8 (13 - 20)

.004^c

n° of lesions, median (IQR)

2 (1 - 4)

3 (1 - 5)

2 (1 - 4)

0.204^a